Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report.

Cohen SE, Sachdev D, Lee SA, Scheer S, Bacon O, Chen MJ, Okochi H, Anderson PL, Kearney MF, Coffey S, Scott H, Grant RM, Havlir D, Gandhi M.

Lancet HIV. 2018 Nov 29. pii: S2352-3018(18)30288-1. doi: 10.1016/S2352-3018(18)30288-1. [Epub ahead of print]

PMID:
30503324
2.

The Pediatric Guideline Adherence and Outcomes (PEGASUS) programme in severe traumatic brain injury: a single-centre hybrid implementation and effectiveness study.

Vavilala MS, King MA, Yang JT, Erickson SL, Mills B, Grant RM, Blayney C, Qiu Q, Chesnut RM, Jaffe KM, Weiner BJ, Johnston BD.

Lancet Child Adolesc Health. 2018 Nov 22. pii: S2352-4642(18)30341-9. doi: 10.1016/S2352-4642(18)30341-9. [Epub ahead of print]

PMID:
30473440
3.

Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.

Murray MI, Markowitz M, Frank I, Grant RM, Mayer KH, Hudson KJ, Stancil BS, Ford SL, Patel P, Rinehart AR, Spreen WR, Margolis DA.

HIV Clin Trials. 2018 Nov 16:1-10. doi: 10.1080/15284336.2018.1511346. [Epub ahead of print]

PMID:
30445896
4.

Repeated False-Positive HIV Test Results in a Patient Taking HIV Pre-Exposure Prophylaxis.

Stekler JD, Violette LR, Niemann L, McMahan VM, Katz DA, Baeten JM, Grant RM, Delaney KP.

Open Forum Infect Dis. 2018 Sep 26;5(9):ofy197. doi: 10.1093/ofid/ofy197. eCollection 2018 Sep.

5.

Impact of Vertebral Fractures and Glucocorticoid Exposure on Height Deficits in Children During Treatment of Leukemia.

Ma J, Siminoski K, Alos N, Halton J, Ho J, Cummings EA, Shenouda N, Matzinger MA, Lentle B, Jaremko JL, Wilson B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lewis VA, Laverdière C, Israels S, Grant RM, Fernandez CV, Dix DB, Couch R, Cairney E, Barr R, Atkinson S, Abish S, Moher D, Rauch F, Ward LM; Canadian STOPP Consortium.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):213-222. doi: 10.1210/jc.2018-01083.

PMID:
30247635
6.

"Losing the Phobia:" Understanding How HIV Pre-exposure Prophylaxis Facilitates Bridging the Serodivide Among Men Who Have Sex With Men.

Koester KA, Erguera XA, Kang Dufour MS, Udoh I, Burack JH, Grant RM, Myers JJ.

Front Public Health. 2018 Sep 6;6:250. doi: 10.3389/fpubh.2018.00250. eCollection 2018.

7.

Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.

Colby DJ, Kroon E, Sacdalan C, Gandhi M, Grant RM, Phanuphak P, Ananworanich J, Robb ML, Phanuphak N.

Clin Infect Dis. 2018 Aug 31;67(6):962-964. doi: 10.1093/cid/ciy321.

PMID:
29961859
8.

Protocol for an HIV Pre-exposure Prophylaxis (PrEP) Population Level Intervention Study in Victoria Australia: The PrEPX Study.

Ryan KE, Mak A, Stoove M, Price B, Fairley CK, Ruth S, Lal L, Asselin J, El-Hayek C, Nguyen L, Batrouney C, Wilson D, Lockwood J, Murphy D, Cornelisse VJ, Roth N, Willcox J, Chang CC, Armishaw J, Tee BK, Penn M, Forgan-Smith G, Williams C, Montgomery J, Byron K, Coelho A, Allen B, Wiggins J, Kelsall J, Vujovic O, West M, Pierce AB, Gallant D, Bell C, de Wit JBF, Hoy JF, Wesselingh SL, Grant RM, Wright EJ.

Front Public Health. 2018 May 29;6:151. doi: 10.3389/fpubh.2018.00151. eCollection 2018.

9.

Bone Morbidity and Recovery in Children With Acute Lymphoblastic Leukemia: Results of a Six-Year Prospective Cohort Study.

Ward LM, Ma J, Lang B, Ho J, Alos N, Matzinger MA, Shenouda N, Lentle B, Jaremko JL, Wilson B, Stephure D, Stein R, Sbrocchi AM, Rodd C, Lewis V, Israels S, Grant RM, Fernandez CV, Dix DB, Cummings EA, Couch R, Cairney E, Barr R, Abish S, Atkinson SA, Hay J, Rauch F, Moher D, Siminoski K, Halton J; Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) Consortium.

J Bone Miner Res. 2018 Aug;33(8):1435-1443. doi: 10.1002/jbmr.3447. Epub 2018 May 22.

PMID:
29786884
10.

Pre-exposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine and Kidney Tubular Dysfunction in HIV-Uninfected Individuals.

Jotwani V, Scherzer R, Glidden DV, Mehrotra M, Defechereux P, Liu A, Gandhi M, Bennett M, Coca SG, Parikh CR, Grant RM, Shlipak MG.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):169-174. doi: 10.1097/QAI.0000000000001654.

PMID:
29767638
11.

The Role of Social Relationships in PrEP Uptake and Use Among Transgender Women and Men Who Have Sex with Men.

Mehrotra ML, Rivet Amico K, McMahan V, Glidden DV, Defechereux P, Guanira JV, Grant RM.

AIDS Behav. 2018 May 12. doi: 10.1007/s10461-018-2151-0. [Epub ahead of print]

PMID:
29754268
12.

The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.

Davis AK, Barsuglia JP, Lancelotta R, Grant RM, Renn E.

J Psychopharmacol. 2018 Jul;32(7):779-792. doi: 10.1177/0269881118769063. Epub 2018 Apr 30.

PMID:
29708042
13.

Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.

Figueroa DB, Tillotson J, Li M, Piwowar-Manning E, Hendrix CW, Holtz TH, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant RM, Bumpus NN.

PLoS One. 2018 Apr 11;13(4):e0195764. doi: 10.1371/journal.pone.0195764. eCollection 2018.

14.

Skating on thin ice: stimulant use and sub-optimal adherence to HIV pre-exposure prophylaxis.

Hojilla JC, Vlahov D, Glidden DV, Amico KR, Mehrotra M, Hance R, Grant RM, Carrico AW.

J Int AIDS Soc. 2018 Mar;21(3):e25103. doi: 10.1002/jia2.25103.

15.

A Mobile Health Strategy to Support Adherence to Antiretroviral Preexposure Prophylaxis.

Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR, Kouyate A, Gilmore HJ, Buchbinder SP, Lester RT, Grant RM, Liu AY.

AIDS Patient Care STDS. 2018 Mar;32(3):104-111. doi: 10.1089/apc.2017.0255.

16.

Characterization of HIV Recent Infection Among High-Risk Men at Public STI Clinics in Mumbai.

Truong HM, Fatch R, Grant RM, Mathur M, Kumta S, Jerajani H, Kellogg TA, Lindan CP.

AIDS Behav. 2018 Jul;22(Suppl 1):70-75. doi: 10.1007/s10461-018-2052-2.

PMID:
29453551
17.

In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?

Mitchell KM, Dimitrov D, Hughes JP, Xia F, Donnell D, Amico KR, Bokoch K, Chitwarakorn A, Bekker LG, Holtz TH, Mannheimer S, Grant RM, Boily MC.

AIDS. 2018 Mar 27;32(6):809-818. doi: 10.1097/QAD.0000000000001766.

18.

Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.

Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, Stirratt M, Rooney JF, Eshleman SH, McNicholl JM, van Griensven F, Holtz TH.

Clin Infect Dis. 2018 May 17;66(11):1712-1721. doi: 10.1093/cid/cix1086.

PMID:
29420695
19.

Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

Clin Infect Dis. 2018 Jul 18;67(3):411-419. doi: 10.1093/cid/ciy083.

PMID:
29415175
20.

Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection.

Eshleman SH, Piwowar-Manning E, Sivay MV, Debevec B, Veater S, McKinstry L, Bekker LG, Mannheimer S, Grant RM, Chesney MA, Coates TJ, Koblin BA, Fogel JM.

J Clin Virol. 2018 Feb - Mar;99-100:67-70. doi: 10.1016/j.jcv.2018.01.003. Epub 2018 Jan 11.

PMID:
29346085
21.

Sex, PrEP, and Stigma: Experiences with HIV Pre-exposure Prophylaxis Among New York City MSM Participating in the HPTN 067/ADAPT Study.

Franks J, Hirsch-Moverman Y, Loquere AS Jr, Amico KR, Grant RM, Dye BJ, Rivera Y, Gamboa R, Mannheimer SB.

AIDS Behav. 2018 Apr;22(4):1139-1149. doi: 10.1007/s10461-017-1964-6.

22.

HIV sero disclosure among men who have sex with men and transgender women on HIV pre-exposure prophylaxis.

Hojilla JC, Mehrotra M, Truong HM, Glidden DV, Amico KR, McMahan V, Vlahov D, Chariyalertsak S, Guanira JV, Grant RM, For The iPrEx Study Team.

AIDS Care. 2018 Apr;30(4):466-472. doi: 10.1080/09540121.2017.1394437. Epub 2017 Oct 28.

23.

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.

Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM; HPTN 067 (ADAPT) study team.

Lancet HIV. 2018 Feb;5(2):e68-e78. doi: 10.1016/S2352-3018(17)30156-X. Epub 2017 Oct 3.

24.

Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users.

Lal L, Audsley J, Murphy DA, Fairley CK, Stoove M, Roth N, Moore R, Tee BK, Puratmaja N, Anderson PL, Leslie D, Grant RM, De Wit J, Wright E; VicPrEP Study Team.

AIDS. 2017 Jul 31;31(12):1709-1714. doi: 10.1097/QAD.0000000000001519.

PMID:
28700394
25.

Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.

Glidden DV, Mulligan K, McMahan V, Anderson PL, Guanira J, Chariyalertsak S, Buchbinder SP, Bekker LG, Schechter M, Grinsztejn B, Grant RM.

J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):177-182. doi: 10.1097/QAI.0000000000001475.

26.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

Markowitz M, Frank I, Grant RM, Mayer KH, Elion R, Goldstein D, Fisher C, Sobieszczyk ME, Gallant JE, Van Tieu H, Weinberg W, Margolis DA, Hudson KJ, Stancil BS, Ford SL, Patel P, Gould E, Rinehart AR, Smith KY, Spreen WR.

Lancet HIV. 2017 Aug;4(8):e331-e340. doi: 10.1016/S2352-3018(17)30068-1. Epub 2017 May 22.

PMID:
28546090
27.

Is pericoital or peri-insemination preexposure prophylaxis effective human immunodeficiency prevention for vaginal exposures?

Seidman DL, Weber S, Grant RM.

Am J Obstet Gynecol. 2017 Aug;217(2):230-231. doi: 10.1016/j.ajog.2017.04.039. Epub 2017 May 4. No abstract available.

PMID:
28479285
28.

Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to Treponema pallidum?

Glidden DV, Mayer K, Grant RM.

Sex Transm Infect. 2017 Aug;93(5):313. doi: 10.1136/sextrans-2017-053212. Epub 2017 Apr 13. No abstract available.

29.

International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status.

Truong HM, Mehrotra M, Montoya O, Lama JR, Guanira JV, Casapía M, Veloso VG, Buchbinder SP, Mayer KH, Chariyalertsak S, Schechter M, Bekker LG, Kallás EG, Grant RM.

Sex Transm Dis. 2017 May;44(5):306-309. doi: 10.1097/OLQ.0000000000000601.

30.

Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations.

Koss CA, Bacchetti P, Hillier SL, Livant E, Horng H, Mgodi N, Mirembe BG, Gomez Feliciano K, Horn S, Liu AY, Glidden DV, Grant RM, Benet LZ, Louie A, van der Straten A, Chirenje ZM, Marrazzo JM, Gandhi M.

AIDS Res Hum Retroviruses. 2017 Mar 2. doi: 10.1089/aid.2016.0202. [Epub ahead of print]

31.

Development and Feasibility of a Real-Time Clinical Decision Support System for Traumatic Brain Injury Anesthesia Care.

Kiatchai T, Colletti AA, Lyons VH, Grant RM, Vavilala MS, Nair BG.

Appl Clin Inform. 2017 Jan 25;8(1):80-96. doi: 10.4338/ACI-2016-10-RA-0164.

32.

Values and Preferences on the Use of Oral Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Multiple Populations: A Systematic Review of the Literature.

Koechlin FM, Fonner VA, Dalglish SL, O'Reilly KR, Baggaley R, Grant RM, Rodolph M, Hodges-Mameletzis I, Kennedy CE.

AIDS Behav. 2017 May;21(5):1325-1335. doi: 10.1007/s10461-016-1627-z. Review.

33.

Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

Gandhi M, Glidden DV, Mayer K, Schechter M, Buchbinder S, Grinsztejn B, Hosek S, Casapia M, Guanira J, Bekker LG, Louie A, Horng H, Benet LZ, Liu A, Grant RM.

Lancet HIV. 2016 Nov;3(11):e521-e528. doi: 10.1016/S2352-3018(16)30153-9. Epub 2016 Aug 31.

34.

Pharmacology supports on-demand PrEP.

Glidden DV, Anderson PL, Grant RM.

Lancet HIV. 2016 Sep;3(9):e405-e406. doi: 10.1016/S2352-3018(16)30114-X. No abstract available.

35.

Transgender Women in Clinical Trials of Pre-Exposure Prophylaxis.

Grant RM, Sevelius JM, Guanira JV, Aguilar JV, Chariyalertsak S, Deutsch MB.

J Acquir Immune Defic Syndr. 2016 Aug 15;72 Suppl 3:S226-9. doi: 10.1097/QAI.0000000000001090.

36.

HIV Serodisclosure and Sexual Behavior During International Travel.

Truong HM, Chen YH, Grasso M, Robertson T, Tao L, Fatch R, Curotto A, McFarland W, Grant RM, Reznick O, Raymond HF, Steward WT.

Sex Transm Dis. 2016 Jul;43(7):459-64. doi: 10.1097/OLQ.0000000000000464.

37.

Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework.

Amico KR, Wallace M, Bekker LG, Roux S, Atujuna M, Sebastian E, Dye BJ, Elharrar V, Grant RM.

AIDS Behav. 2017 May;21(5):1361-1375. doi: 10.1007/s10461-016-1458-y.

38.

PO-60 - Renal tumors with extensive vascular disease: management challenges in a pediatric series from the Hospital for Sick Children.

Zamperlini-Netto G, Zanette A, Wehbi E, Williams S, Grant RM, Brandao LR.

Thromb Res. 2016 Apr;140 Suppl 1:S198-9. doi: 10.1016/S0049-3848(16)30193-1. Epub 2016 Apr 8.

PMID:
27161746
39.

Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.

Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM.

AIDS. 2016 Jul 31;30(12):1973-83. doi: 10.1097/QAD.0000000000001145. Review.

40.

PrEP adherence among trans women in Brazil-access needed for this key population - Authors' reply.

Sevelius J, Deutsch MB, Glidden DV, Grant RM.

Lancet HIV. 2016 May;3(5):e200-1. doi: 10.1016/S2352-3018(16)30023-6. No abstract available.

PMID:
27126486
41.

The Effect of Depressive Symptoms on Adherence to Daily Oral PrEP in Men who have Sex with Men and Transgender Women: A Marginal Structural Model Analysis of The iPrEx OLE Study.

Mehrotra ML, Glidden DV, McMahan V, Amico KR, Hosek S, Defechereux P, Mayer KH, Veloso VG, Bekker LG, Avelino-Silva VI, Schechter M, Grant RM.

AIDS Behav. 2016 Jul;20(7):1527-34. doi: 10.1007/s10461-016-1415-9.

42.

HIV moments and pre-exposure prophylaxis.

Grant RM, Glidden DV.

Lancet. 2016 Apr 9;387(10027):1507-8. doi: 10.1016/S0140-6736(16)30125-8. Epub 2016 Apr 7. No abstract available.

43.

Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

Glidden DV, Amico KR, Liu AY, Hosek SG, Anderson PL, Buchbinder SP, McMahan V, Mayer KH, David B, Schechter M, Grinsztejn B, Guanira J, Grant RM.

Clin Infect Dis. 2016 May 1;62(9):1172-7. doi: 10.1093/cid/ciw022. Epub 2016 Jan 20.

44.

Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial.

Kuebler PJ, Shaw BI, Leadabrand KS, Mehrotra ML, Grant RM, Kallás EG, Nixon DF.

J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):184-8. doi: 10.1097/QAI.0000000000000923.

45.

Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis: A Meta-Analysis of Randomized Placebo-Controlled Trials.

Yacoub R, Nadkarni GN, Weikum D, Konstantinidis I, Boueilh A, Grant RM, Mugwanya KK, Baeten JM, Wyatt CM.

J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):e115-8. doi: 10.1097/QAI.0000000000000906. No abstract available.

46.

HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.

Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, Kallas EG, Chariyalertsak S, Grant RM; iPrEx investigators.

Lancet HIV. 2015 Dec;2(12):e512-9. doi: 10.1016/S2352-3018(15)00206-4. Epub 2015 Nov 6.

47.

What people want from sex and preexposure prophylaxis.

Grant RM, Koester KA.

Curr Opin HIV AIDS. 2016 Jan;11(1):3-9. doi: 10.1097/COH.0000000000000216. Review.

PMID:
26569183
48.

Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment.

Grant RM, Smith DK.

Open Forum Infect Dis. 2015 Aug 26;2(4):ofv126. doi: 10.1093/ofid/ofv126. eCollection 2015 Dec. Review.

49.

The Safety of Tenofovir-Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B.

Solomon MM, Schechter M, Liu AY, McMahan VM, Guanira JV, Hance RJ, Chariyalertsak S, Mayer KH, Grant RM; iPrEx Study Team.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):281-6. doi: 10.1097/QAI.0000000000000857. Erratum in: J Acquir Immune Defic Syndr. 2016 Jul 1;72 (3):e82.

50.

Editorial Commentary: Keeping Our Eyes on the Prize: No New HIV Infections With Increased Use of HIV Pre-exposure Prophylaxis.

Koester KA, Grant RM.

Clin Infect Dis. 2015 Nov 15;61(10):1604-5. doi: 10.1093/cid/civ783. Epub 2015 Sep 1. No abstract available.

Supplemental Content

Loading ...
Support Center